AIHTA - Publications - Search - Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019. HSO: 41st Prioritisation.

[thumbnail of HSO_41st_Prioritisation.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

For the 41st prioritisation (10/2019), ten drugs were filtered out of 578 identified and were sent to
prioritisation. Of these, three drugs were ranked as 'highly relevant' by the expert panel, seven as
'relevant' and none as 'not relevant'. For 'highly relevant' drugs, further information including, for
example, abstracts of phase III studies and licensing status is contained in this document.

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Series Name:HSO: 41st Prioritisation
Deposited on:13 Nov 2019 14:06
Last Modified:15 Jul 2020 18:00

Repository Staff Only: item control page